智通财经APP获悉，兆科眼科-B(06622)涨近4%，截至发稿，涨3.88%，报1.34港元，成交额286万港元。
消息面上，兆科眼科近日宣布，国家药监局已于近日正式受理公司药物NVK002（0.01%低剂量阿托品）的简易新药申请。NVK002是该公司最具发展潜力的核心药物之一，用于控制儿童及青少年的近视加深。NVK002之简易新药申请是基于兆科眼科在中国进行的第III期临床研究。值得一提的是，截至目前，国内仅有一款硫酸阿托品滴眼液在售，为兴齐眼药的兴齐美欧品，于2024年3月11日获批。
智通财经APP获悉，兆科眼科-B(06622)涨近4%，截至发稿，涨3.88%，报1.34港元，成交额286万港元。
消息面上，兆科眼科近日宣布，国家药监局已于近日正式受理公司药物NVK002（0.01%低剂量阿托品）的简易新药申请。NVK002是该公司最具发展潜力的核心药物之一，用于控制儿童及青少年的近视加深。NVK002之简易新药申请是基于兆科眼科在中国进行的第III期临床研究。值得一提的是，截至目前，国内仅有一款硫酸阿托品滴眼液在售，为兴齐眼药的兴齐美欧品，于2024年3月11日获批。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.